Atlas Trials

Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.

Clinical trial NCT04343144 · UNKNOWN

Trial details

NCT number
NCT04343144
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
COVID19- Infection With SARS-CoV-2 Virus
Start date
2020-04-15
Primary completion
2020-07-31
Enrollment
92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.